NCT05773768 EHRA-PATHS: Clinical and Health Economic Evaluation of New Care Pathways
| NCT ID | NCT05773768 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Medical Center Groningen |
| Condition | Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,300 participants |
| Start Date | 2024-03-28 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,300 participants in total. It began in 2024-03-28 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In elderly atrial fibrillation (AF) patients, AF is usually a manifestation of risk factors and comorbidities not only limited to cardiovascular diseases. Especially in elderly often more than two comorbidities are present. The presence of comorbidities also affects outcomes in AF patients. Current healthcare systems are single-disease focused, which increases the risk of underdiagnosing, replicating diagnostic tests and adverse drug-drug interactions, placing a high burden on healthcare costs. Healthcare systems and hospitals are in need of new care pathways to address the complexity of multimorbid AF patients and to reduce costs. The EHRA-PATHS consortium set out to address this need for change in management for multimorbid, elderly AF patients in Europe through the development of new care pathways. The aim of this study is to evaluate the current management of risk factors and comorbidities, and subsequently implement the newly developed care pathways and evaluate if these pathways lead to better management of risk factors and comorbidities in multimorbid, elderly AF patients, compared to current standard care.
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed atrial fibrillation (paroxysmal, persistent or permanent) * ≥65 years of age * Willing and able to participate and to attend the scheduled follow-up visits. Exclusion Criteria: * Atrial fibrillation episode was due to a trigger (i.e. postoperative, infection, hyperthyroidism etc.) * Life expectancy of less than 1 year * Participation in another clinical study (registry studies not included) * Severe cognitive impairment / dementia (defined based on MMSE and CDR scoring systems)
Frequently Asked Questions
Who can join the NCT05773768 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05773768 currently recruiting?
Yes, NCT05773768 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Medical Center Groningen to inquire about joining.
Where is the NCT05773768 trial being conducted?
This trial is being conducted at Groningen, Netherlands.
Who is sponsoring the NCT05773768 clinical trial?
NCT05773768 is sponsored by University Medical Center Groningen. The trial plans to enroll 1,300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.